ErbB2 growth factor receptor, a marker for neuroendocrine cells?

Jens Standop, Mahefatiana Andrianifahanana, Nicolas Moniaux, Matthias Schneider, Alexis Ulrich, Randall E. Brand, James Lowell Wisecarver, Julia A. Bridge, Markus W. Büchler, Thomas E. Adrian, Surinder Kumar Batra, Parviz M. Pour

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Aims: The overexpression of ErbB2 in pancreatic cancer has been reported with a varying incidence ranging between 1 and 80%. Our routine examination, however, revealed a consistently strong immunoreactivity of three anti-ErbB2 growth factor receptor antibodies in pancreatic islets and intrapancreatic ganglia. To validate our findings and to understand the reasons for the reported differences in the frequency of ErbB2 overexpression in pancreatic cancer, the following studies were performed. Materials and Methods: Tissue samples from 12 normal pancreata, 7 surgical chronic pancreatitis cases, 21 primary pancreatic adenocarcinomas, 9 metastatic pancreatic adenocarcinomas, and 4 islet cell tumors were subjected to immunohistochemical examination using antibodies from three manufacturers. Cultured human islet cells and pancreatic cancer cell lines, as well as samples from the gastrointestinal tract, the CNS, and the adrenal gland were included in the study. For comparison, mammary cancer tissue and mammary cancer cells, as well as selected tissues from Syrian golden hamsters, were used. To verify the results. Western blot and Northern slot-blot analyses were performed. Results: Pancreatic cancer cells, in vitro and in vivo, showed a remarkable heterogeneity in the immunostaining of ErbB2, ranging from very faintly to strongly stained. On the other hand, in both humans and hamsters, a consistently strong immunostaining was found in the Langerhans' islets, in the ganglia of intrapancreatic and extrapancreatic nerves, as well as in the CNS, spinal cord and adrenal gland. Conclusions: ErbB2 appears to play an important role in neuroendocrine tissues and is probably involved in the development and functional regulation of these cells. The concomitant expression of these factors and islet cell hormones very likely results in the activation of multiple growth-promoting pathways in pancreatic cancer and its aggressive behavior.

Original languageEnglish (US)
Pages (from-to)44-58
Number of pages15
JournalPancreatology
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2005

Fingerprint

Neuroendocrine Cells
Growth Factor Receptors
Pancreatic Neoplasms
Islets of Langerhans
Breast Neoplasms
Adrenal Glands
Ganglia
Adenocarcinoma
Islet Cell Adenoma
Antibodies
Mesocricetus
Chronic Pancreatitis
Cricetinae
Northern Blotting
Gastrointestinal Tract
Pancreas
Spinal Cord
Western Blotting
Hormones
Cell Line

Keywords

  • Adrenal gland
  • CNS
  • ErbB2 growth factor receptor
  • Ganglia
  • Islets of langerhans
  • Neuroendocrine cells
  • Pancreas

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Standop, J., Andrianifahanana, M., Moniaux, N., Schneider, M., Ulrich, A., Brand, R. E., ... Pour, P. M. (2005). ErbB2 growth factor receptor, a marker for neuroendocrine cells? Pancreatology, 5(1), 44-58. https://doi.org/10.1159/000084490

ErbB2 growth factor receptor, a marker for neuroendocrine cells? / Standop, Jens; Andrianifahanana, Mahefatiana; Moniaux, Nicolas; Schneider, Matthias; Ulrich, Alexis; Brand, Randall E.; Wisecarver, James Lowell; Bridge, Julia A.; Büchler, Markus W.; Adrian, Thomas E.; Batra, Surinder Kumar; Pour, Parviz M.

In: Pancreatology, Vol. 5, No. 1, 01.01.2005, p. 44-58.

Research output: Contribution to journalArticle

Standop, J, Andrianifahanana, M, Moniaux, N, Schneider, M, Ulrich, A, Brand, RE, Wisecarver, JL, Bridge, JA, Büchler, MW, Adrian, TE, Batra, SK & Pour, PM 2005, 'ErbB2 growth factor receptor, a marker for neuroendocrine cells?', Pancreatology, vol. 5, no. 1, pp. 44-58. https://doi.org/10.1159/000084490
Standop J, Andrianifahanana M, Moniaux N, Schneider M, Ulrich A, Brand RE et al. ErbB2 growth factor receptor, a marker for neuroendocrine cells? Pancreatology. 2005 Jan 1;5(1):44-58. https://doi.org/10.1159/000084490
Standop, Jens ; Andrianifahanana, Mahefatiana ; Moniaux, Nicolas ; Schneider, Matthias ; Ulrich, Alexis ; Brand, Randall E. ; Wisecarver, James Lowell ; Bridge, Julia A. ; Büchler, Markus W. ; Adrian, Thomas E. ; Batra, Surinder Kumar ; Pour, Parviz M. / ErbB2 growth factor receptor, a marker for neuroendocrine cells?. In: Pancreatology. 2005 ; Vol. 5, No. 1. pp. 44-58.
@article{403ea7b801f64a13bd8bee95a4a69fd3,
title = "ErbB2 growth factor receptor, a marker for neuroendocrine cells?",
abstract = "Background/Aims: The overexpression of ErbB2 in pancreatic cancer has been reported with a varying incidence ranging between 1 and 80{\%}. Our routine examination, however, revealed a consistently strong immunoreactivity of three anti-ErbB2 growth factor receptor antibodies in pancreatic islets and intrapancreatic ganglia. To validate our findings and to understand the reasons for the reported differences in the frequency of ErbB2 overexpression in pancreatic cancer, the following studies were performed. Materials and Methods: Tissue samples from 12 normal pancreata, 7 surgical chronic pancreatitis cases, 21 primary pancreatic adenocarcinomas, 9 metastatic pancreatic adenocarcinomas, and 4 islet cell tumors were subjected to immunohistochemical examination using antibodies from three manufacturers. Cultured human islet cells and pancreatic cancer cell lines, as well as samples from the gastrointestinal tract, the CNS, and the adrenal gland were included in the study. For comparison, mammary cancer tissue and mammary cancer cells, as well as selected tissues from Syrian golden hamsters, were used. To verify the results. Western blot and Northern slot-blot analyses were performed. Results: Pancreatic cancer cells, in vitro and in vivo, showed a remarkable heterogeneity in the immunostaining of ErbB2, ranging from very faintly to strongly stained. On the other hand, in both humans and hamsters, a consistently strong immunostaining was found in the Langerhans' islets, in the ganglia of intrapancreatic and extrapancreatic nerves, as well as in the CNS, spinal cord and adrenal gland. Conclusions: ErbB2 appears to play an important role in neuroendocrine tissues and is probably involved in the development and functional regulation of these cells. The concomitant expression of these factors and islet cell hormones very likely results in the activation of multiple growth-promoting pathways in pancreatic cancer and its aggressive behavior.",
keywords = "Adrenal gland, CNS, ErbB2 growth factor receptor, Ganglia, Islets of langerhans, Neuroendocrine cells, Pancreas",
author = "Jens Standop and Mahefatiana Andrianifahanana and Nicolas Moniaux and Matthias Schneider and Alexis Ulrich and Brand, {Randall E.} and Wisecarver, {James Lowell} and Bridge, {Julia A.} and B{\"u}chler, {Markus W.} and Adrian, {Thomas E.} and Batra, {Surinder Kumar} and Pour, {Parviz M.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1159/000084490",
language = "English (US)",
volume = "5",
pages = "44--58",
journal = "Pancreatology",
issn = "1424-3903",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - ErbB2 growth factor receptor, a marker for neuroendocrine cells?

AU - Standop, Jens

AU - Andrianifahanana, Mahefatiana

AU - Moniaux, Nicolas

AU - Schneider, Matthias

AU - Ulrich, Alexis

AU - Brand, Randall E.

AU - Wisecarver, James Lowell

AU - Bridge, Julia A.

AU - Büchler, Markus W.

AU - Adrian, Thomas E.

AU - Batra, Surinder Kumar

AU - Pour, Parviz M.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background/Aims: The overexpression of ErbB2 in pancreatic cancer has been reported with a varying incidence ranging between 1 and 80%. Our routine examination, however, revealed a consistently strong immunoreactivity of three anti-ErbB2 growth factor receptor antibodies in pancreatic islets and intrapancreatic ganglia. To validate our findings and to understand the reasons for the reported differences in the frequency of ErbB2 overexpression in pancreatic cancer, the following studies were performed. Materials and Methods: Tissue samples from 12 normal pancreata, 7 surgical chronic pancreatitis cases, 21 primary pancreatic adenocarcinomas, 9 metastatic pancreatic adenocarcinomas, and 4 islet cell tumors were subjected to immunohistochemical examination using antibodies from three manufacturers. Cultured human islet cells and pancreatic cancer cell lines, as well as samples from the gastrointestinal tract, the CNS, and the adrenal gland were included in the study. For comparison, mammary cancer tissue and mammary cancer cells, as well as selected tissues from Syrian golden hamsters, were used. To verify the results. Western blot and Northern slot-blot analyses were performed. Results: Pancreatic cancer cells, in vitro and in vivo, showed a remarkable heterogeneity in the immunostaining of ErbB2, ranging from very faintly to strongly stained. On the other hand, in both humans and hamsters, a consistently strong immunostaining was found in the Langerhans' islets, in the ganglia of intrapancreatic and extrapancreatic nerves, as well as in the CNS, spinal cord and adrenal gland. Conclusions: ErbB2 appears to play an important role in neuroendocrine tissues and is probably involved in the development and functional regulation of these cells. The concomitant expression of these factors and islet cell hormones very likely results in the activation of multiple growth-promoting pathways in pancreatic cancer and its aggressive behavior.

AB - Background/Aims: The overexpression of ErbB2 in pancreatic cancer has been reported with a varying incidence ranging between 1 and 80%. Our routine examination, however, revealed a consistently strong immunoreactivity of three anti-ErbB2 growth factor receptor antibodies in pancreatic islets and intrapancreatic ganglia. To validate our findings and to understand the reasons for the reported differences in the frequency of ErbB2 overexpression in pancreatic cancer, the following studies were performed. Materials and Methods: Tissue samples from 12 normal pancreata, 7 surgical chronic pancreatitis cases, 21 primary pancreatic adenocarcinomas, 9 metastatic pancreatic adenocarcinomas, and 4 islet cell tumors were subjected to immunohistochemical examination using antibodies from three manufacturers. Cultured human islet cells and pancreatic cancer cell lines, as well as samples from the gastrointestinal tract, the CNS, and the adrenal gland were included in the study. For comparison, mammary cancer tissue and mammary cancer cells, as well as selected tissues from Syrian golden hamsters, were used. To verify the results. Western blot and Northern slot-blot analyses were performed. Results: Pancreatic cancer cells, in vitro and in vivo, showed a remarkable heterogeneity in the immunostaining of ErbB2, ranging from very faintly to strongly stained. On the other hand, in both humans and hamsters, a consistently strong immunostaining was found in the Langerhans' islets, in the ganglia of intrapancreatic and extrapancreatic nerves, as well as in the CNS, spinal cord and adrenal gland. Conclusions: ErbB2 appears to play an important role in neuroendocrine tissues and is probably involved in the development and functional regulation of these cells. The concomitant expression of these factors and islet cell hormones very likely results in the activation of multiple growth-promoting pathways in pancreatic cancer and its aggressive behavior.

KW - Adrenal gland

KW - CNS

KW - ErbB2 growth factor receptor

KW - Ganglia

KW - Islets of langerhans

KW - Neuroendocrine cells

KW - Pancreas

UR - http://www.scopus.com/inward/record.url?scp=21044445280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044445280&partnerID=8YFLogxK

U2 - 10.1159/000084490

DO - 10.1159/000084490

M3 - Article

C2 - 15775699

AN - SCOPUS:21044445280

VL - 5

SP - 44

EP - 58

JO - Pancreatology

JF - Pancreatology

SN - 1424-3903

IS - 1

ER -